N. Seebacher

发表

Regulation of microRNAs function by circular RNAs in human cancer

Q. Kan, Z. Duan, F. Hornicek, 2017, Oncotarget.

Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma

Z. Duan, Yu‐quan Wei, F. Hornicek, 2019, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma

C. Garbutt, Z. Duan, F. Hornicek, 2018, Cell Death & Disease.

Lysosomal membrane stability plays a major role in the cytotoxic activity of the anti-proliferative agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT).

D. Richardson, D. Kalinowski, S. Sahni, 2016, Biochimica et biophysica acta.

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma

Z. Duan, F. Hornicek, N. Seebacher, 2018, EBioMedicine.

Cutaneous manifestations of COVID‐19: diagnosis and management

N. Seebacher, Saxon D. Smith, J. Kirkham, 2022, The Medical journal of Australia.

A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC

D. Richardson, N. Seebacher, P. Jansson, 2016, Cell Death & Disease.

Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo.

D. Richardson, D. Kalinowski, N. Seebacher, 2012, Journal of medicinal chemistry.

The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones.

D. Richardson, D. Kalinowski, S. Sahni, 2015, Pharmacological research.

Di-2-pyridylketone 4,4-Dimethyl-3-thiosemicarbazone (Dp44mT) Overcomes Multidrug Resistance by a Novel Mechanism Involving the Hijacking of Lysosomal P-Glycoprotein (Pgp)*

D. Richardson, S. Sahni, N. Seebacher, 2015, The Journal of Biological Chemistry.

Tumour Microenvironment Stress Promotes the Development of Drug Resistance

N. Seebacher, P. Jansson, J. Skoda, 2021, Antioxidants.

Novel strategies to prevent the development of multidrug resistance (MDR) in cancer.

Huirong Shi, Q. Kan, Z. Duan, 2017, Oncotarget.

Advances in sarcoma gene mutations and therapeutic targets.

Z. Duan, F. Hornicek, N. Seebacher, 2018, Cancer treatment reviews.

Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma

C. Garbutt, Z. Duan, F. Hornicek, 2018, Cell Death & Disease.

Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance.

D. Richardson, N. Seebacher, P. Jansson, 2016, Free radical biology & medicine.

Clinical development of targeted and immune based anti-cancer therapies

A. M. Merlot, G. Porter, N. Seebacher, 2019, Journal of experimental & clinical cancer research : CR.

Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma

Z. Duan, F. Hornicek, N. Seebacher, 2019, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Does Portrayal of Skin Tone in Gender-Affirming Literature Represent Diversity?

Krishna S. Vyas, S. Morrison, T. Satterwhite, 2020, LGBT health.

Application of liquid biopsy in bone and soft tissue sarcomas: Present and future.

Z. Duan, F. Hornicek, N. Seebacher, 2018, Cancer letters.

Global Interest in Gender Affirmation Surgery: A Google Trends Analysis.

S. Morrison, N. Seebacher, Jacson K. Shen, 2018, Plastic and reconstructive surgery.

Glucose modulation induces reactive oxygen species and increases P‐glycoprotein‐mediated multidrug resistance to chemotherapeutics

D. Richardson, N. Seebacher, P. Jansson, 2015, British journal of pharmacology.

Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter*

D. Richardson, N. Seebacher, P. Jansson, 2015, The Journal of Biological Chemistry.

Clinical development of targeted and immune based anti-cancer therapies

A. M. Merlot, G. Porter, N. Seebacher, 2019, Journal of Experimental & Clinical Cancer Research.

The antibody response of haematological malignancies to COVID-19 infection and vaccination

N. Seebacher, 2022, British Journal of Cancer.

Patient Endothelial Colony-Forming Cells to Model Coronary Artery Disease Susceptibility and Unravel the Role of Dysregulated Mitochondrial Redox Signalling

S. Grieve, G. Figtree, P. Psaltis, 2021, Antioxidants.

Novel strategies to prevent the development of multidrug resistance (MDR) in cancer

Huirong Shi, Q. Kan, Z. Duan, 2017, Oncotarget.

Good's syndrome associated with multiple basal cell carcinomas: a case report

N. Seebacher, M. Polcz, Michelle Wu, 2023, The Medical journal of Australia.

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma

Z. Duan, F. Hornicek, N. Seebacher, 2018, EBioMedicine.

“Global Interest in Gender Affirmation Surgery

N. Seebacher, Jacson K. Shen, Shane D. Morrison, 2018, Plastic and Reconstructive Surgery.